Predictors of Sorafenib Response in Patients With Advanced Hepatocellular Carcinoma
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 80
- 主要终点
- Predictors of sorafenib response
研究概览
简要总结
Evaluating the nutrition status of patients with advanced HCC who received sorafenib.
Using the pretreatment nutrition status and quality of life as predictors to sorafenib response
详细描述
This a cross sectional study will be conducted on 100 HCC treated with sorafenib Data were gathered from medical records, including
age sex body weight and height (BMI) pre-therapy laboratory counts of white cells, neutrophils, lymphocytes, monocyte, hemoglobin and platelets; bilirubin, albumin and globulin concentration, AST, ALT, AFP, PT and CONC
Barcelona Clinic Liver Cancer Stage (BCLC) of all patients
The neutrophil-to- lymphocyte ratio (NLR) was calculated by dividing the neutrophil count by the lymphocyte count.
The platelet- to-lymphocyte ratio (PLR) was calculated by dividing the platelet count by the lymphocyte count.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HCC recieved sorafenib
排除标准
- •Patient refuse to participate
- •Patients recieving other treatment modalities
结局指标
主要结局
Predictors of sorafenib response
时间窗: Augest 2023 to March 2024
The neutrophil-to- lymphocyte ratio
assessment of nutrition status
时间窗: Augest 2023 to March 2024
Prognostic nutrition index
Assess the quality of life
时间窗: Augest 2023 to March 2024
using FACT Hepatobiliary Symptom Index
次要结局
未报告次要终点
研究者
Mona Mohammed Abdelrhman
Principal investigator
Sohag University